{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Thymosin Alpha-1",
    "short_name": "Thymosin Alpha-1",
    "aliases": [
      "thymalfasin",
      "ta1"
    ],
    "classification": {
      "category": "approved_human",
      "needs_prescription": true,
      "notes": "Classification describes what Thymosin Alpha-1 is and the general domain where it appears."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-18",
      "human_use_note": "This entry summarizes how the compound is discussed/used in the real world without endorsing use or providing instructions."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk rating is conservative and reflects known uncertainties, evidence limitations, and potential for non-obvious harms.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "What it is and why it is studied are summarized here in a conservative, evidence-bounded way.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "studied are summarized here in a conservative, evidence-bounded way",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "source_id": "33362999",
        "source_type": "journal_article",
        "evidence_grade": "human_interventional",
        "title": "Thymosin alpha 1: A comprehensive review of the literature",
        "year": 2020,
        "url": "https://pubmed.ncbi.nlm.nih.gov/33362999/",
        "notes": "Clinical review context; not a protocol or dosing guide."
      },
      {
        "id": "E2",
        "source_id": "37110771",
        "source_type": "journal_article",
        "evidence_grade": "human_interventional",
        "title": "Thymosin α1 and Its Role in Viral Infectious Diseases",
        "year": 2023,
        "url": "https://pubmed.ncbi.nlm.nih.gov/37110771/",
        "notes": "Review of mechanisms + clinical contexts; not a protocol or dosing guide."
      },
      {
        "id": "E3",
        "source_id": "FDA-TA1-BULK-2024",
        "source_type": "regulatory",
        "evidence_grade": "unknown",
        "title": "FDA document referencing Thymosin alpha-1 bulk drug substances (regulatory context)",
        "year": 2024,
        "url": "https://www.fda.gov/media/183892/download",
        "notes": "Regulatory/compounding context; not clinical efficacy proof."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-18",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Thymosin Alpha-1",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-18T19:45:38+00:00",
        "change_type": "content_update",
        "summary": "Added conservative evidence refs for TA1 identity/approval context (no instructions).",
        "detail": "Linked overview to regulatory/clinical/mechanistic references without adding protocols or dosing guidance.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-18T19:58:03+00:00",
        "change_type": "content_update",
        "summary": "Replaced Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. evidence entries with specific sources (no instructions).",
        "detail": "Filled TA1 evidence metadata for E1–E3 with specific identifiers/links. No dosing/protocol content added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_immune_modulation"
      ]
    },
    "slug": "thymosin-alpha-1",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "Thymosin alpha-1 is an immune-modulating peptide studied in infectious disease and oncology-adjunct contexts. In wellness communities, it is usually discussed as immune support during high stress or frequent illness seasons. The biggest real-world variables are sourcing quality and medical appropriateness for immune-related conditions.",
      "benefits": [
        "Immune support interest during frequent illness seasons",
        "Resilience support interest during high stress or heavy training blocks",
        "Adjunct interest in chronic infection discussions in online communities",
        "Interest in immune calibration and inflammatory balance discussions"
      ],
      "side_effects_common": [
        "Injection-site irritation or redness",
        "Fatigue",
        "Headache",
        "Mild flu-like feeling"
      ],
      "side_effects_serious": [
        "Allergic reaction with hives, facial swelling, or trouble breathing",
        "High fever with severe body aches",
        "Severe worsening of autoimmune symptoms"
      ],
      "who_should_be_cautious": [
        "Autoimmune disease",
        "Organ transplant recipients or people on immunosuppressive therapy",
        "Active infection with significant systemic symptoms",
        "Pregnancy or breastfeeding",
        "Children and adolescents"
      ]
    }
  },
  "canonical_name": "Thymosin Alpha-1",
  "interactions": {
    "drug_classes": [
      "immunosuppressants",
      "anti-infectives-antimicrobials",
      "immune-modulation-infection-risk"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Thymosin alpha-1 is an immune-modulating peptide studied in infectious disease and oncology-adjunct contexts. In wellness communities, it is usually discussed as immune support during high stress or frequent illness seasons. The biggest real-world variables are sourcing quality and medical appropriateness for immune-related conditions.",
    "benefits": [
      "Immune support interest during frequent illness seasons",
      "Resilience support interest during high stress or heavy training blocks",
      "Adjunct interest in chronic infection discussions in online communities",
      "Interest in immune calibration and inflammatory balance discussions"
    ],
    "side_effects_common": [
      "Injection-site irritation or redness",
      "Fatigue",
      "Headache",
      "Mild flu-like feeling"
    ],
    "side_effects_serious": [
      "Allergic reaction with hives, facial swelling, or trouble breathing",
      "High fever with severe body aches",
      "Severe worsening of autoimmune symptoms"
    ],
    "who_should_be_cautious": [
      "Autoimmune disease",
      "Organ transplant recipients or people on immunosuppressive therapy",
      "Active infection with significant systemic symptoms",
      "Pregnancy or breastfeeding",
      "Children and adolescents"
    ]
  }
}
